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Abstract WW-domain-containing oxidoreductase (WWOX)
is the tumour suppressor gene from the common fragile site
FRA16D, whose altered expression has been observed in
tumours of various origins. Its suppressive role and influence
on basic cellular processes such as proliferation and apoptosis
have been confirmed in many in vitro and in vivo studies.
Moreover, its protein is thought to take part in the regulation
of tissue morphogenesis and cell differentiation. However, its
role in colon cancer formation remains unclear. The aim of
this study was to characterize the influence of WWOX on the
process of colon cancerogenesis, the basic features of the
cancer cell and its expression profiles. Multiple biological
tests, microarray experiments and quantitative reverse tran-
scriptase (RT)-PCR were performed on two colon cancer cell
lines, HT29 and SW480, which differ in morphology, expres-
sion of differentiation markers, migratory characteristics and
metastasis potential and which represent negative (HT29) and
low (SW480) WWOX expression levels. The cell lines were
subjected to retroviral transfection, inducting WWOX overex-
pression. WWOX was found to have diverse effects on prolif-
eration, apoptosis and the adhesion potential of modified cell
lines. Our observations suggest that in the HT29 colon cancer
cell line, increased expression of WWOX may result in the
transition of cancer cells into a more normal colon epithelium
phenotype, while in SW480, WWOX demonstrated well-
known tumour suppressor properties. Our results also suggest
that WWOX does not behave as classical tumour suppressor
gene, and its influence on cell functioning is more global and
complicated.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers
in Western countries. According to American Cancer Society
in 2013, it will account for 9% of new cancer cases and 9% of
tumour-associated deaths, independently on gender [1]. In
Poland, CRC has been defined as a tumour of the highest
growth rate and was ranked second highest in men and third
highest in women in mortality statistics in 2010 [2]. Despite
progress in understanding the cancer transformation of colon
cells, clinical and histopathological classifications are still
commonly used [3].
The majority of CRC cases are sporadic, and three distinct
developmental molecular pathways have been described,
based on molecular changes within colon epithelial cells. All
three depict alterations in genome integrity control and DNA
repair mechanisms. The most common is chromosomal insta-
bility pathway (CIN) characterized by allelic losses, chromo-
somal amplifications and mutations within suppressor genes
and oncogenes (e.g. APC, KRAS, BRAF and TP53). The
second pathway, microsatellite instability (MSI), is expressed
as frameshift mutations within short, tandemly repeated nu-
cleotide sequences which arise as a consequence of disorders
in the DNAmismatch repair system. It mostly not only affects
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MMR genes such asMSH2,MLH1 and mutS homolog (MSH)
6 but also concerns β-catenin, Bcl-2-associated X protein
(BAX) and TGFβIIR genes. The third pathway, the CpG
methylator phenotype (CIMP), involves epigenetic gene si-
lencing through DNA methylation. CIMP cases tend to have
v-raf murine sarcoma viral oncogene homolog B (BRAF) and
Kirsten rat sarcoma viral oncogene homolog (KRAS) muta-
tions and rarely, P53 [4, 5]. It is important to note that
colorectal tumours are characterized by different changes at
the genomic level characteristic of the particular pathway by
which they are derived and reveal diverse clinical features,
which are included in the classification created by Jass et al.
and Oginio et al. [5–7].
WW-domain-containing oxidoreductase (WWOX) is a tu-
mour suppressor gene from the common fragile site FRA16D,
whose altered expression has been observed in many tumour
types, i.e. breast [8, 9], gastric [10], prostate [11], non-small
cell lung cancer [12] andWilms’ tumours [13]. Its suppressive
role and its influence on basic cellular processes such as
proliferation and apoptosis have been confirmed in many
in vitro and in vivo studies [11, 14–17]. As the WWOX
protein is a partner of several transcription factors, it probably
also takes part in controlling the expression of genes involved
in tissue morphogenesis and cell differentiation [18–20].
Moreover, a correlation between WWOX reduction and clin-
ical factors such as stage, grade and disease progression has
been observed in such cases as gastric [10, 21], urinary blad-
der [22], ovary [23, 24] and breast cancer [25, 26].
However, its role in colon cancer cell transformation is not
well defined. In normal colon cells, its expression is quite low,
and only individual neuroendocrine cells were found to be
positive for WWOX staining, while Goblet cells along the
large bowel were negative [27]. In CRC samples, patients
without disease recurrence during the observation period were
found to demonstrate increased WWOX messenger RNA
(mRNA) expression, with no correlation with other clinical
factors. In the same study, a negative correlation was observed
between expression of WWOX and cyclin E1, KI67 and
proapoptoticBAX/B cell lymphoma 2(BCl2) ratio and positive
correlation with v-erb-b2 avian erythroblastic leukemia viral
oncogene homolog 2 (ERBB) 4 [28]. The last mentioned
correlation seems to be intriguing, as it was previously shown
that WWOX binds to two cytoplasmic regions of ERBB4
responsible for YAP interactions, and this physical binding
results in prevention of ERBB4 translocation to nucleus,
which in result may lead to dysregulation of ERBB4 tran-
scriptional activity [29]. In breast cancer samples, the presence
of membranousWWOX and ERBB4 strongly correlated with
favourable outcome, and such coexpression seemed to have
prognostic significance [30].
The aim of this study was to characterize howWWOXmay
be involved in colon cancerogenesis or cancer progression and
how it influences the basic cancer cell features (i.e. viability,
proliferation and apoptosis) and modifies cell expression pro-
file. The chosen colon cancer cell lines differ with regard to
morphology, expression of differentiation markers, migratory
characteristics and metastasis potential [31, 32]. Both repre-
sent the CIN pathway but differ in ploidy, are MSI stable and
overexpress mutated P53 [33].
As HT29 demonstrates negative WWOX expression and
SW480 low expression, the cell lines were subjected to retro-
viral transfection to increase WWOX expression.
Materials and methods
Cell culture
The HT29 cell line was cultured in McCoy’s 5X Modified
Medium (Gibco, Life Technologies) and SW480 in RPMI-
1640 (Gibco, Life Technologies). Both media were supple-
mented with 10 % FBS (Gibco, Life Technologies), 1 % L-
glutamine and 1 % Penicillium, Neomycinium and
Streptomycinium (PNS; Gibco, Life Technologies).
Stable transfection
Cells were transfected with retroviral vector pLNCX2, pro-
duced by PT67 packing cells, in two variants: an empty vector
(experiment reference) and a vector harbouring WWOX com-
plementary DNA (cDNA). A neomycin resistance gene was
incorporated in both vectors. In order to increase the effec-
tiveness of transduction, polybrene (Sigma) at a concentration
of 8 μg/μl was added to the infection medium. The selection
was performed with G418 (Aplichem) at a selective concen-
tration of 400 μg/ml for seven doses every 48 h.
Biological tests
All biological tests were performed in minimum three inde-
pendent replicates.
Invasion assay
The invasion assay was performed with the BioCoat Matrigel
Invasion Chambers, 24-well plate (BD, Immunogen), accord-
ing to the manufacturer’s protocol. Both variants of examined
cells were seeded at a concentration of 1.5×105 per chamber.
The number of cells which transferred the basic membrane
was analyzed with ImageJ 1.34 s software (Wayane Rasband,
National Institutes of Health, USA; http://rsb.info.nih.gov/ij/)
Growth in soft agar
In order to perform this test, two layers of agarose (Serva)
were prepared: a lower layer at a concentration of 0.9 % in full
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medium and an upper layer at a concentration of 0.3 % in cell
suspension. The cells were seeded at a concentration of 1×
104 cells/ml in each well in a six-well plate. After 23 days of
culturing, visualization was preformed with nitro blue tetra-
zolium (NBT) (Sigma). Colonies were counted with ImageJ
1.34 s software.
ECM adhesion
The ability of transducted cell lines to adhere to extracellular
matrix (ECM) proteins was assessed using the CytoSelect™
48-Well Cell Adhesion Assay (Cell Biolabs, Inc) according to
the manufacturer’s protocol. The ability of the cells to adhere
to fibronectin, collagen I, collagen IV, laminin and fibrinogen
was assessed. The concentration of cells used in this experi-
ment was 1×106 cells/ml. The absorbance was measured
using a BioTek plate reader.
Proliferation, viability and apoptosis—triplex assay
A triplex assay was performed measuring the difference be-
tween the cell variants with regard to viability, proliferation
and apoptosis. All the tests were performed on the same cell
culture in order to avoid potential differences in population
and culture conditions. Cell viability was assessed using
alamarBlue®Cell Viability Reagent (Life Technologies). Data
was collected after five 1-h intervals, at a fluorescence exci-
tation wavelength of 550 nm and emission of 590 nm.
A DELFIA® Cell Proliferation Kit (Perkin Elmer) was
used to assess the differences in proliferation between the
strains while DELFIA DNA Fragmentation Assay (based on
TUNEL assay; PerkinElmer) assesses the differences in apo-
ptosis. Both cell lines in both variants were seeded on 96-well
plate Wallac Isoplate TC (PerkinElmer) at a concentration of
2×104 cells per well. Blank and background wells were also
included in the experiment.
The reading of fluorescence for Europium and Samarium
was performed with VICTOR X4™ (PerkinElmer) plate
reader.
Statistical analysis of biological tests
The results were presented as means, and the statistical sig-
nificance was assessed with Student’s t test. The confidence
level was >95 % (p<0.05).
RNA isolation and cDNA synthesis
Total RNA was isolated from cell culture using the TRIzol
reagent (Life Technologies). Following which, 10 μg of the
RNA was reverse transcribed to cDNA in a total volume of
100 μl with ImProm-II reverse transcriptase (RT) (Promega).
The reaction conditions were as follows: 5 min incubation at
25 °C, 60 min at 42 °C, heating at 70 °C for 15 min. Finally,
2 μl of cDNA diluted with sterile deionized water was used in
the PCR reaction.
The cDNA used in the microarray experiments was
subjected to an additional hydrolysis stage (30 min at
65 °C) followed by neutralization and purification. More
detailed information on the procedure is available upon
request.
Microarray procedures
Microarray flip dye experiments on cancer cell lines were
performed with Human OneArray™ Whole Genome Micro-
array v 5.1 (Phalanx Biotech) in four replicates. Each sample
was hybridized against Universal Human Reference RNA
(Stratagene) pooled from ten cancer cell lines. Single-
stranded cDNA samples were labelled with Cy3 and Cy5
using ULS™ Labelling Kit (Kreatech Diagnostics,
Netherlands).
The preparation of a slide for hybridization included pre-
wash in ethanol and pre-hybridization according to manufac-
turer’s protocol. Hybridization was performed in a humidity
chamber filled with 2× SSPE buffer at 42 °C for 16–18 h.
Post-hybridization washes were performed with the following
buffers: 1× SSPE/0.03 % SDS (2 min, 42 °C), 1× SSPE
(2 min, RT) and 0.1× SSPE (rinsed several times, RT).
Scanning and preliminary normalization was carried out
with ProScanArray (Perkin Elmer, USA) and ScanArray Ex-
press, respectively. Further LOWESS and statistical analysis
was carried out with the TM4 software suite provided by The
Institute for Genomic Research at http://www.tm4.org/. After
modified T test analysis, the fold change of differentially
expressed genes was calculated, and the Pantherdb online
ontology application (www.pantherdb.org) was used to
classify them according to ontological terms.
The results were regarded as significant at p<0.05.
Real-time RT-PCR analysis
Real-time RT-PCR was used to assess the relative expression
level of selected molecular markers in order to validate the
microarray experiments. A LightCycler 480 II (Roche) was
used to perform real-time RT-PCR reactions, which were run
in duplicate. PCR products were detected via SYBR Green I
and a qPCR Core Kit for SYBR Green I (Eurogentec).
The relative mRNA expressions of genes controlling a
variety of cellular processes were analyzed: apoptosis (BAX,
BCL2 and BIRC5), proliferation and cell cycle (KI67, cyclin E1
(CCNE1) and cyclin D1 (CCND1)), signal transduction (epi-
dermal growth factor receptor (EGFR), ERBB4 JM-a) and
others (TP73, CDH1). Real-time RT-PCR was used to assess
WWOX transfection efficiency. The mRNA expression level
of studied genes was normalized to two reference genes
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(RPLP0 and RPS17). The calibrator for each reaction was
Universal Human Reference RNA (Stratagene). The primers
used were intron spanning in order to avoid the amplification
of genomic DNA, and detection temperature was designed to
avoid non-specific/primer-dimer products. The relative gene
expression level was calculated according to Roche algorithm
[34].
Immunoblotting
Total protein was extracted from cells using RIPA protein
extraction buffer (50 mM Tris-HCl (pH 8.0), 150 mM NaCl,
0.5 % Na Doc, 0.1 % NP-40, 0.1 % SDS, 2 mM EDTA) with
protease, phosphatase inhibitor cocktail and 1 mM PMSF
(Sigma-Aldrich, Germany). The Bradford method (Bio-Rad
Laboratories) was used for determination of protein concen-
tration, according to the manufacturer’s protocol.
Following this, 10 % SDS-PAGE gel electrophoresis was
performed on 60 μg of protein, followed again by PVDF
membrane (Sigma-Aldrich, Germany) transfer. Subsequently,
the membranes were pre-incubated in 5 % non-fat milk in
Tris-buffered saline and Tween 20 (TBST) (20 mM Tris-HCl,
500mMNaCl, Tween-20, pH 7.5) for 1 h at room temperature
and incubated for 19 h at 4 °C in selected primary antibodies
(Santa Cruz Biotechnology Inc., USA) at a concentration of
1:100.
Afterwards, TBST washes were performed followed by a
2-h incubation in secondary antibodies conjugated with alka-
line phosphatase (Sigma-Aldrich, Germany). Post-incubation
washes were repeated in the same conditions as before.
Novex® AP Chromogenic Substrate (Invitrogen, USA) was
used to induce the colour reaction. Band visualization was
performed on the membranes, and ImageJ 1.34 s software
(Wayane Rasband, National Institutes of Health, USA, http://
rsb.info.nih.gov/ij/) was used for densitometric analysis of
protein levels. The results were established as optical density




Increased WWOX mRNA and protein expression was identi-
fied in both colon cancer cell lines (Figs. 1 and 2; Tables 1 and
2). In SW480, the fold change in WWOX mRNA expression
between transfection variants was more than 137 times, in
HT29 more than 37 times. The transfection procedure had no
influence on native WWOX expression in both cell lines.
Microarray analysis
For both modified colon cancer cell lines, the expression of
multiple genes was found to be altered as a result of WWOX
overexpression.
The microarray analysis of SW480vector versus
SW480/WWOX cell lines revealed over 800 genes which
were differentially expressed to a significant degree
(p<0.05). The Panther Classification System online ontol-
ogy application was able to classify over 200 genes into 54
Fig. 1 Confirmation of SW480 cell line transfection on the protein level
and calculated relative protein expression. The values are mean±SD.
*p<0.05. Lines 1–3 SW480/vector, 4–6 SW480/WWOX
Fig. 2 Confirmation of HT29 cell line transfection on the protein level
and calculated relative protein expression. The values are mean±SD.
*p<0.05. Lines 1–3 HT29/WWOX, 4–6 HT29/vector
9294 Tumor Biol. (2014) 35:9291–9301
signalling pathways. The remaining genes were marked as
unclassified as a result of the complexity of their cell
function. The most modified pathways were as follows:
wingless-type MMTV integration site family (WNT) (13
genes), integrin signalling pathway (10 genes), inflamma-
tion regulated via chemokines and cytokines (10 genes),
PDGF pathway (9 genes), cadherin pathway (8 genes) and
the transforming growth factor (TGF)-β pathway (7
genes). All identified signalling pathways, with number
of genes are available in the sumpelemtary data section.
The same ontology program classified received genes ac-
cording to their function in biological processes, molecular
function and cellular component. It is important to note
that modifications were identified in the expression of
genes regulating the cell cycle of DNA replication, apo-
ptosis and cell motion.
For the HT29 experimental cell line, over 900 genes were
differentially expressed to a significant degree (p<0.05). The
obtained genes were assigned to 93 signalling pathways. The
most highly modified pathways were similar to those found in
the SW480 cell line, also included the WNT pathway (14
genes), integrin signalling pathway (12 genes), inflammation
regulated via chemokins and cytokins (11 genes), apoptosis (7
genes) and the TGF-β pathway (7 genes). According to other
ontology terms, cell cycle and cell motion gene expression
were found to be elevated while the expression of the genes
responsible for apoptosis was decreased.
Overall, WWOX overexpression resulted in similar geno-
mic modifications in both colon cancer cell lines except for the
TGF-β pathway, apoptosis and proliferation. Detailed ontol-
ogy analysis, for both colon cancer cell lines, is available in






WWOX 0.24 32.78 137.42
KI67 1.65 0.79 −2.08
CCNE1 0.81 0.33 −2.46
EGFR 1.29 0.52 −2.49
HER4 JMa-1 0.16 1.21 7.77
PTEN 0.05 0.25 4.92
CDH1 0.04 0.05 1.27
CCND1 15.62 10.36 −1.51
TP73 2.05 1.20 −1.72
BIRC5 0.03 0.03 −1.02
BAX 0.37 0.38 1.00
BCL2 0.02 0.02 1.14
Fig. 3 Changes in the viability of a SW480 and b HT29 cell line
variants. Fluorescence is expressed in relative reference units (RFU).
The values are mean±SD. *p<0.05
Table 2 The changes of the relative expression level of cancer-related





WWOX 0.09 3.34 37.82
BCL2 0.00051 0.01318 25.64
HER4-JMa-1 0.02 0.44 19.81
BIRC5 0.55 0.00 −428.52
CCND1 0.23 0.03 −8.41
KI67 0.35 0.03 −10.26
BAX 1.70 0.29 −5.86
EGFR 0.19 0.02 −8.29
PTEN 4.37 0.08 −56.72
CCNE1 0.20 0.16 −1.26
CDH1 5.14 4.99 −1.03
TP73 0.19 0.16 −1.15
Bold entries indicate genes with significant change in expression on
mRNA level
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Online Resource 1. Microarray data was submitted to GEO
Database (reference series: GSE 54301).
Biological tests
Triplex assay
Viability Decreased viability was noted for variants overex-
pressing WWOX in both examined cell lines. However, in
SW480/WWOX, the decrease was 20 % in comparison to the
SW480 vector and was statistically significant at the first two
measurement points. In HT29/WWOX, the decrease was
10 % but insignificant at all measurement points (p>0.05)
(Fig. 3a, b).
Proliferation and apoptosis
For both cell lines, contrasting results were obtained in both
tests. In the SW480 cell line, a statistically significant
(p<0.05) 20 % decrease in proliferation potential for cell
variant harbouring WWOX cDNAwas observed in compari-
son to the experimental reference, the SW480 vector. A 20 %
increase of apoptosis was also observed in SW480/WWOX;
however, the difference between the examined variants was
not statistically significant (p>0.05) (Fig. 4a, b).
Fig. 4 The effect of WWOX overexpression on a proliferation and b
apoptosis in the SW480 cell line. Fluorescence is expressed in relative
reference units (RFU). Eu europium used as antibody label in prolifera-
tion assay, Sm samarium used as antibody label in apoptosis assay. The
values are mean±SD. *p<0.05
Fig. 5 The effect of WWOX overexpression on a proliferation and b
apoptosis in the HT29 cell line. Fluorescence is expressed in relative
reference units (RFU). Eu europium used as antibody label in prolifera-
tion assay, Sm samarium used as antibody label in apoptosis assay. The
values are mean±SD. *p<0.05
Fig. 6 Adhesion to ECM proteins for the SW480 transfected cell line.
The values are mean±SD. *p<0.05
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In contrast, a 40 % increase in proliferation potential and
60% decline in apoptosis were seen in a HT29 cell line variant
overexpressingWWOX. Both results were statistically signif-
icant (p<0.05) (Fig. 5a, b)
ECM adhesion
Statistically significant (p<0.05) decreases in SW480/
WWOX cell line adhesion was observed: Adhesion to fibro-
nectin dropped to a third, while adhesion to laminin I halved.
The process of adhesion to the rest of the examined ECM
proteins did not reveal any differences between the two vari-
ants of the SW480 colon cancer cell line (Fig. 6).
In contrast, the HT29/WWOX cell line variant, in compar-
ison to the HT29/vector, demonstrated a 2-fold increase in
adhesion to collagen I and an increase in adhesion to fibro-
nectin by more than a third. Both results were statistically
significant (p<0.05). There were no other differences in ad-
hesion between HT29 WWOX/HT29 vectors to other exam-
ined ECM proteins (Fig. 7).
Invasion assay
Statistically significant (p<0.05) changes were seen in inva-
sion for both cell lines of variants overexpressing WWOX. In
SW480/WWOX, invasion was 50 % higher than the level
measured in the SW480 vector, i.e. the variant without
WWOX cDNA. Regarding the other colon cancer cell line,
the ability to invade the basal membrane was seen in the
HT29/WWOX cell variant (Fig. 8).
Growth in soft agar
Complete inhibition of growth in suspension was seen in both
cell lines overexpressing the WWOX gene (p<0.05) (Fig. 9).
Real-time RT-PCR
In the SW480/WWOX colon cancer cell line, the expression
of genes regulating the cell cycle (CCNE1, KI67) and signal
Fig. 7 Adhesion to ECM proteins for the HT29 transfected cell line. The
values are mean±SD. *p<0.05
Fig. 8 Invasion assay and calculated difference in migration for both
transfected colon cancer cell lines. The values are mean±SD. *p<0.05
Fig. 9 Growth in soft agar and calculated number of colonies for both
cell lines. The values are mean±SD. *p<0.05
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transduction (EGFR) were found to be significantly downreg-
ulated, in contrast to the expression of ERBB4 JMa-1 and the
suppressor gene PTEN. More detailed information, i.e. mean
gene mRNA expression and calculated fold change for each
gene between cell line variants, is presented in Table 1.
In the other colon cancer cell line, mRNA expression of
BCL2 and ERBB4 JMa-1 was seen to be upregulated in the
presence of WWOX. The remaining examined genes were
downregulated in HT29/WWOX in comparison to the HT29
vector cell line variant. Detailed information is presented in
Table 2.
Microarray validation
The mRNA expression levels of the BAX and oestrogen
receptor (ESR) 2 genes, whose expression was altered in the
HT29 cell line, were analyzed with real-time RT-PCR. The
changes in the level of expression of selected genes in micro-
array analysis positively correlated with the real-time RT-PCR
results. The results obtained from both techniques confirmed
similar trends of gene expression profiles, i.e. downregulation
of BAX (the fold change in expression was about 1.5 times in
microarray data and 5-fold decrease in RT-PCR) and upregu-
lation of ESR2 (1.24 upregulation in microarray data, 10-fold
in real-time RT-PCR; the relative expression values were
0.105 vs 1.16 for HT29 vector vs HT29/WWOX, respective-
ly). The downregulation of BAX was also noticed on the
protein level (1.9-fold decrease) (Table 2, Fig. 10).
Discussion
The function of WWOX in the suppression of cancerogenesis
has been confirmed previously in cancers of hormone-related
tissues, including breast, ovary and prostate [9, 11, 17, 23, 35],
but also in cancers from gastrointestinal tract, such as gastric
[10], oesophageal [36], pancreatic [14] and liver tissue [37].
This suppressive effect has been mainly assigned to inhibition
of the proliferation and induction of apoptosis. In our present
study, we observed WWOX-dependent changes in prolifera-
tion and apoptosis in two colon cancer cell lines HT29 and
SW480, which vary in terms of epithelial-mesenchymal tran-
sition (EMT) markers, WNTactivity and stemness signatures.
SW480 has a high EMTmarkers expression, with a migratory
capacity phenotype and gene expression similar to those of a
microdissected tumour epithelium and is a good model of an
invasive tumour while the HT29 cell line has been ranked
lower in terms of EMT and humanized intestinal stem cell
signature (HuISC) signatures, and its expression profile is the
closest to the gene expression profile of bulk tumour tissue
cells. The HT29 cell line seems to be most similar to small
intestine enterocytes and, in specific culture conditions, is able
to show distinct differentiation similar to the enterocyte path-
way [38]. Our experiments seem to confirm and delineate
further behavioural differences between HT29 and SW480
and indicate the diverse effects of WWOX functioning in
colon cancerogenesis.
SW480 overexpressing WWOX showed a statistically sig-
nificant inhibition of proliferation (p=0.04) and a strong ten-
dency towards initiation of apoptosis (p=0.07), which is con-
sistent with previous results observed in breast cancer cell
lines (BT-474, MDA-MB-231, HCC1937) [17], lung cancer
cell lines (A549, H460, H1299) [39, 40], ovarian cancer line
(A2780) [41], liver cancer (SMMC-7721) [16] and other cell
lines [42]. The results observed for the SW480 cell line, as for
other mentioned cancer cell lines, seem to be an effect of
WWOX restoration, as SW480 has moderately low WWOX
expression (relative expression 0.23).
The microarray data presented herein reveals changes in
the expression of genes regulating apoptosis and proliferation,
which have been confirmed by real-time RT-PCR to be asso-
ciated with a significant downregulation of genes connected
with cell cycle and proliferation (CCND1, CCNE1 and
KI67). However, no WWOX-induced changes were ob-
served in the transcription of apoptosis-related genes (BAX,
BCL2, BIRC5), whose expression was observed to correlate
withWWOX in colon tumour specimens [28] and other cancer
tissues [13, 26, 43].
Contrary to the SW480, the results of the HT29 biolog-
ical tests indicated a statistically significant upregulation of
proliferation and apoptosis inhibition. This discrepancy be-
tween colon cancer cell lines seems to reflect the changes
on the transcriptome level indicated by microarray experi-
ments and real-time RT-PCR. Although real-time RT-PCR
analysis revealed decreased expression of CCND1, CCNE1
and KI67 in HT29/WWOX, microarray analysis identi-
fied more than 53 genes which play a role in cell cycle
regulation, with the overall effect being proliferation
Fig. 10 Validation of microarray experiments. The values are mean±
SD;*p<0.05; Lines 1–4 HT29/vector, 5–8 HT29/WWOX
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induction. Among the genes assigned to regulate prolifera-
tion, ESR2 merits special attention, whose increased ex-
pression was confirmed by real-time RT-PCR. Previously,
only oestrogen receptor alpha expression had been found to
correlate with WWOX expression [26, 44]. However, ESR2
gene expression is characteristic feature of a normal colon
epithelium, and it is downregulated in CRC; in addition, its
decreased expression has been associated with Duke’s stage
[45], and, according to Konstantinopoulos et al., the loss of
ESR2 expression is associated with the disability of cancer
cells to differentiate [46]. Hence, its elevated expression,
associated with WWOX gene overexpression, may result in
a higher cell proliferation/differentiation potential.
In addition, the discrepancy between SW480 and HT29
regarding the effect of WWOX on proliferation and apoptosis
may also be explained by the diverse effect of WWOX on the
TGF-β pathway revealed by the microarray study. The
TGF-β pathway is a major regulator of proliferation, apopto-
sis, cell differentiation and ECM remodelling. However, its
function in cancerogenesis is ambiguous. In a normal colon
epithelium and in the early stages of cancer formation, this
pathway induces apoptosis and inhibits tumour growth. In
advanced stages, it loses its suppressive function, leading to
tumour progression [47, 48]. Previously, it has been shown
that upon pathway initiation, the TGF-β1 protein binds to
membranous Hyal-2 and, as a result, forms a complex with
WWOX. This complex relocates to the nucleus where the
activation of mothers against decapentaplegic homolog
(SMAD)-driven promoters is thought to be controlled, thus
regulating cell death and growth [49].
In the SW480 cell line with ectopically increased WWOX
expression, we observed downregulation of genes belonging
to the canonical TGF pathway (i.e. SMAD1 and SMAD2),
while an increase of SMAD2 and two growth differentiation
factors (GDF), i.e. GDF11 and GDF6, was observed in HT29.
These factors are bone morphogenetic proteins (BMPs),
which are secreted in stromal cells and induce colon cell
differentiation, constituting an alternative TGF-β pathway.
Although their highest expression was observed in the upper
parts of the colon tops, they are also expressed in the basal
crypts, albeit in an inactive state [50, 51]. GDF11 is known to
play a role in colon cancerogenesis, and it has been indicated
that it may influence the proliferation and differentiation of
stem cells [52].
The overall results obtained for the HT29 cell line may
reflect alterations of the TGF-β pathway, which redirects
HT29 cells overexpressing WWOX towards the phenotype of
a normal colon cell from the upper parts of the colon crypts.
This observation is consistent with the description of the
character of the HT29 cell line, insofar that they demonstrate
many biochemical and physiological features of normal colo-
rectal epithelial cells [53], which may be further enhanced via
WWOX overexpression.
In our study, the transfected cell lines were found to have
different adhesion properties to ECM proteins. SW480/
WWOX demonstrated decreased adhesion to fibronectin, con-
sistent with previous findings for ovarian cancer cell lines
PEO1, SCOV3 [35] and laminin, which has been identified
as a predictive factor for tumour progression [54], whereas
HT29/WWOX demonstrated increased adhesion to fibronec-
tin and collagen I. These differences imply that diverse adhe-
sion may reflect the process of cell remodelling of HT29.
The diverse effect of WWOX observed in these two colon
cancer cell lines may also reflect the different stage of
cancerogenesis progression. In this case, the transcription
mechanisms may react in different ways to changes in
WWOX protein level.
However, the influence WWOX on the aggressiveness of
cancer cells, measured as growth in soft agar, seems to be
identical for both experimental colon cancer cell lines and
consistent with previous findings [11, 14, 15, 19] insofar that
a statistically significant inhibition of colony formation was
noted in both cell lines overexpressing WWOX. Regard the
invasion assay, the same results was observed for both cell
lines. As in the MDA-MB 231 breast cancer cell line, in-
creased expression of WWOX resulted in increased invasion
through basal membrane, which may be connected with
WWOX regulation of cell motility, and may perhaps exert an
influence on tissue remodelling [19].
Conclusions
The study investigated the role of the WWOX gene in
colon cancerogenesis. We have noticed reduction of pro-
liferation rate and adhesion to ECM proteins in SW480
colon cancer cell line overexpressing WWOX, which
observations seem to confirm the well-described tumour
suppressor properties of WWOX gene. In the other exper-
imental colon cancer cell line HT29, increased expression
of investigated gene resulted in the opposite effect on
apoptosis, proliferation and adhesion seen in SW480 cell
line. However, taking under consideration cell line fea-
tures, our observations suggest that increased expression
of WWOX may transform HT29 cancer cells into a more
normal colon epithelium phenotype. Our results also sug-
gest that WWOX does not behave as classical tumour
suppressor gene and its influence on cell functioning is
more global and complicated. Our observations might be
also an effect of chromosomal instability and mutated p53
in both cell lines, which generate high genomic complex-
ity in which WWOX might be also involved. Further
studies ought to be conducted in order to specify the role
of the WW-domain-containing oxidoreductase gene in the
process of colon cancer formation.
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